Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090977358> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2090977358 endingPage "42" @default.
- W2090977358 startingPage "37" @default.
- W2090977358 abstract "Pimecrolimus cream 1% (Elidel, SDZ ASM 981) is a novel, non-steroid inflammatory cytokine inhibitor, effective in the treatment of atopic dermatitis. Here, we evaluate the treatment of chronic hand dermatitis with pimecrolimus cream 1%.To determine pimecrolimus blood concentrations, and evaluate the safety, tolerability and efficacy following application of pimecrolimus cream 1% to subjects with chronic hand dermatitis.In this open-label, multiple-topical-dose, non-controlled, pharmacokinetic study, pimecrolimus cream 1% was applied twice daily to dorsal and palmar areas (affected and unaffected) of both hands. Evening applications (except day 8) were immediately followed by overnight occlusion (> or =6 h). Full pharmacokinetic profile (days 1, 8 and 22), trough concentrations (days 3 and 15), physical examinations, laboratory measurements and adverse events were recorded. Efficacy was assessed via Investigators' Global Assessment (IGA), total key signs and symptoms and the subject's overall self-assessment.Twelve patients completed the study. The majority of pimecrolimus blood concentrations (73.6%) remained below the limit of quantitation (0.1 ng/ml). The maximum concentration observed was 0.91 ng/ml and the maximum area under the concentration-time curve from 0-12 h post dose was 7.6 ng.h/ml. Treatment was well tolerated locally and systemically. No serious adverse events occurred; 4/13 subjects showed a total of 6 adverse events at the application site: burning (n=4), and pruritus (n=2). No clinically relevant or drug-related changes were observed. Clear efficacy of the treatment was shown by all 3 assessment methods. Disease state at day 22 had improved in 11 (85%) subjects compared with baseline (IGA).Twice daily topical treatment of moderate to severe chronic hand dermatitis with pimecrolimus cream 1% results in low pimecrolimus blood levels, is well tolerated, safe, and effective." @default.
- W2090977358 created "2016-06-24" @default.
- W2090977358 creator A5041025684 @default.
- W2090977358 creator A5045524890 @default.
- W2090977358 creator A5061144468 @default.
- W2090977358 creator A5085831636 @default.
- W2090977358 creator A5090582633 @default.
- W2090977358 date "2003-01-01" @default.
- W2090977358 modified "2023-10-14" @default.
- W2090977358 title "Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective" @default.
- W2090977358 cites W1965831364 @default.
- W2090977358 cites W1988528294 @default.
- W2090977358 cites W2046244045 @default.
- W2090977358 cites W2047826268 @default.
- W2090977358 cites W2088186226 @default.
- W2090977358 doi "https://doi.org/10.1159/000070939" @default.
- W2090977358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12835546" @default.
- W2090977358 hasPublicationYear "2003" @default.
- W2090977358 type Work @default.
- W2090977358 sameAs 2090977358 @default.
- W2090977358 citedByCount "55" @default.
- W2090977358 countsByYear W20909773582012 @default.
- W2090977358 countsByYear W20909773582014 @default.
- W2090977358 countsByYear W20909773582015 @default.
- W2090977358 countsByYear W20909773582018 @default.
- W2090977358 crossrefType "journal-article" @default.
- W2090977358 hasAuthorship W2090977358A5041025684 @default.
- W2090977358 hasAuthorship W2090977358A5045524890 @default.
- W2090977358 hasAuthorship W2090977358A5061144468 @default.
- W2090977358 hasAuthorship W2090977358A5085831636 @default.
- W2090977358 hasAuthorship W2090977358A5090582633 @default.
- W2090977358 hasConcept C112705442 @default.
- W2090977358 hasConcept C126322002 @default.
- W2090977358 hasConcept C16005928 @default.
- W2090977358 hasConcept C197934379 @default.
- W2090977358 hasConcept C2776028589 @default.
- W2090977358 hasConcept C2778329239 @default.
- W2090977358 hasConcept C2778375690 @default.
- W2090977358 hasConcept C2909675724 @default.
- W2090977358 hasConcept C2911091166 @default.
- W2090977358 hasConcept C71924100 @default.
- W2090977358 hasConcept C98274493 @default.
- W2090977358 hasConceptScore W2090977358C112705442 @default.
- W2090977358 hasConceptScore W2090977358C126322002 @default.
- W2090977358 hasConceptScore W2090977358C16005928 @default.
- W2090977358 hasConceptScore W2090977358C197934379 @default.
- W2090977358 hasConceptScore W2090977358C2776028589 @default.
- W2090977358 hasConceptScore W2090977358C2778329239 @default.
- W2090977358 hasConceptScore W2090977358C2778375690 @default.
- W2090977358 hasConceptScore W2090977358C2909675724 @default.
- W2090977358 hasConceptScore W2090977358C2911091166 @default.
- W2090977358 hasConceptScore W2090977358C71924100 @default.
- W2090977358 hasConceptScore W2090977358C98274493 @default.
- W2090977358 hasIssue "1" @default.
- W2090977358 hasLocation W20909773581 @default.
- W2090977358 hasLocation W20909773582 @default.
- W2090977358 hasOpenAccess W2090977358 @default.
- W2090977358 hasPrimaryLocation W20909773581 @default.
- W2090977358 hasRelatedWork W1574078569 @default.
- W2090977358 hasRelatedWork W1982670399 @default.
- W2090977358 hasRelatedWork W1993713631 @default.
- W2090977358 hasRelatedWork W2114862870 @default.
- W2090977358 hasRelatedWork W2336509786 @default.
- W2090977358 hasRelatedWork W2365074602 @default.
- W2090977358 hasRelatedWork W2924436684 @default.
- W2090977358 hasRelatedWork W2993530656 @default.
- W2090977358 hasRelatedWork W3146934054 @default.
- W2090977358 hasRelatedWork W2512502926 @default.
- W2090977358 hasVolume "207" @default.
- W2090977358 isParatext "false" @default.
- W2090977358 isRetracted "false" @default.
- W2090977358 magId "2090977358" @default.
- W2090977358 workType "article" @default.